Genmab A/S (GMAB) Projected to Announce Quarterly Earnings on Thursday

Key Points

• Genmab is expected to report Q3 2026 results before the market opens on November 5. Analysts forecast earnings of $0.37 per share and revenue of $1.20 billion, compared with the company’s prior-quarter EPS beat of $0.54 versus a $0.37 consensus estimate.
• Shares have surged 28.3% following positive Phase 3 results for petosemtamab combined with Keytruda, which reduced the risk of death by 50% in a head-and-neck cancer trial and improved overall survival and response rates.
• Investor sentiment has strengthened, with JPMorgan upgrading Genmab to “overweight” and the stock receiving a consensus “Moderate Buy” rating. However, full trial data, regulatory review and commercialization remain outstanding.

Genmab A/S (NASDAQ:GMAB - Get Free Report) is expected to be posting its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect the company to announce earnings of $0.37 per share and revenue of $1.20 billion for the quarter. Investors can find conference call details on the company's upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Thursday, November 5, 2026 at 12:00 PM ET.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last announced its quarterly earnings data on Thursday, August 6th. The company reported $0.54 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.37 by $0.17. Genmab A/S had a net margin of 19.08% and a return on equity of 14.89%. The company had revenue of $1.16 billion for the quarter, compared to analysts' expectations of $1.12 billion. On average, analysts expect Genmab A/S to post $1.22 EPS for the current fiscal year and $1.59 EPS for the next fiscal year.

Genmab A/S Stock Up 28.3%

NASDAQ GMAB opened at $57.29 on Thursday. The company has a debt-to-equity ratio of 0.81, a current ratio of 2.46 and a quick ratio of 2.44. The company's 50 day simple moving average is $36.20 and its 200 day simple moving average is $30.36. Genmab A/S has a 12 month low of $23.62 and a 12 month high of $59.97. The company has a market capitalization of $35.75 billion, a P/E ratio of 45.11, a PEG ratio of 2.01 and a beta of 0.81.

Key Headlines Impacting Genmab A/S

Here are the key news stories impacting Genmab A/S this week:

• Positive Sentiment: Genmab reported that the Phase 3 LiGeR-HN1 trial met both primary endpoints in first-line, PD-L1-positive recurrent/metastatic head and neck squamous cell carcinoma. Petosemtamab combined with Merck’s pembrolizumab reduced the risk of death by 50% versus pembrolizumab alone, with a statistically significant improvement in overall survival and objective response rate, regardless of patients’ HPV status. Genmab Phase 3 trial announcement
• Positive Sentiment: The results support expectations that petosemtamab could become a meaningful commercial product and potentially establish a new treatment standard. Analysts described the results as a significant “hat trick,” while reports highlighted the drug’s potential in combination with Keytruda. Barron’s report on Genmab’s record high
• Positive Sentiment: JPMorgan upgraded its rating on GMAB, and TD Cowen said the stock could rise, adding to the positive analyst sentiment. Heavy call-option activity also indicates strong speculative interest following the clinical announcement. JPMorgan rating upgrade
• Neutral Sentiment: Genmab plans to discuss the results with global regulators and submit the full dataset for presentation at a future medical meeting. Investors still lack the complete efficacy and safety details, and regulatory approval and commercialization remain ahead. Genmab Phase III data discussion

Analyst Ratings Changes

A number of brokerages recently weighed in on GMAB. JPMorgan Chase & Co. upgraded shares of Genmab A/S from a "neutral" rating to an "overweight" rating in a report on Monday. Truist Financial lifted their price target on shares of Genmab A/S from $40.00 to $45.00 and gave the stock a "buy" rating in a research report on Wednesday, October 7th. Guggenheim upped their price target on Genmab A/S from $45.00 to $54.00 and gave the company a "buy" rating in a report on Monday, October 5th. New Street Research set a $43.00 price objective on Genmab A/S in a research report on Wednesday, July 22nd. Finally, HC Wainwright increased their price objective on Genmab A/S from $40.00 to $50.00 and gave the company a "buy" rating in a research report on Wednesday, October 7th. One analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and three have given a Hold rating to the stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $44.39.

Genmab A/S Company Profile

Genmab A/S is a biotechnology company headquartered in Copenhagen, Denmark, focused on discovering and developing differentiated antibody-based medicines for the treatment of cancer and other serious diseases. The company uses proprietary antibody technologies, including DuoBody and HexaBody, to create therapies designed to engage the immune system or target specific disease-related proteins.

Genmab's marketed and partnered products include DARZALEX (daratumumab) for multiple myeloma, developed with Johnson & Johnson; EPKINLY (epcoritamab) for certain types of B-cell lymphoma, developed with AbbVie; and Tivdak (tisotumab vedotin) for cervical cancer, developed with Seagen.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.